Christopher Ryan Sullivan Sells 7,979 Shares of Avalo Therapeutics (NASDAQ:AVTX) Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Ryan Sullivan sold 7,979 shares of Avalo Therapeutics stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $16.77, for a total value of $133,807.83. Following the transaction, the chief financial officer owned 25,318 shares of the company’s stock, valued at $424,582.86. The trade was a 23.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christopher Ryan Sullivan also recently made the following trade(s):

• On Thursday, April 2nd, Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock. The shares were sold at an average price of $17.15, for a total value of $136,857.00.

Avalo Therapeutics Price Performance

AVTX opened at $17.76 on Friday. Avalo Therapeutics, Inc. has a 12-month low of $3.39 and a 12-month high of $20.72. The business has a 50 day moving average of $15.54 and a 200-day moving average of $16.01. The stock has a market cap of $404.75 million, a price-to-earnings ratio of -3.10 and a beta of 0.93.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $1.17. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of ($0.21) million. As a group, analysts expect that Avalo Therapeutics, Inc. will post -19.07 earnings per share for the current year.

Hedge Funds Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AVTX. Geode Capital Management LLC raised its stake in Avalo Therapeutics by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 110,460 shares of the company’s stock worth $552,000 after purchasing an additional 2,648 shares in the last quarter. Quadrature Capital Ltd bought a new stake in Avalo Therapeutics in the 2nd quarter valued at about $55,000. Velan Capital Investment Management LP grew its position in shares of Avalo Therapeutics by 38.4% during the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company’s stock worth $773,000 after purchasing an additional 43,000 shares in the last quarter. Nantahala Capital Management LLC increased its holdings in shares of Avalo Therapeutics by 10.6% during the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock worth $4,965,000 after purchasing an additional 95,000 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Avalo Therapeutics by 7,066.8% during the second quarter. Bank of America Corp DE now owns 406,571 shares of the company’s stock worth $2,029,000 after purchasing an additional 400,898 shares during the period. 87.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AVTX has been the subject of several research analyst reports. BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Avalo Therapeutics in a report on Tuesday, March 24th. HC Wainwright increased their price target on shares of Avalo Therapeutics from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Mizuho upgraded Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, Guggenheim started coverage on Avalo Therapeutics in a research note on Monday, February 2nd. They set a “buy” rating and a $50.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.25.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.